CapsoVision, Inc. (NASDAQ: CV), a commercial-stage medical technology company specializing in AI-powered capsule endoscopy solutions, has successfully completed its initial public offering (IPO) on the Nasdaq Capital Market. The company offered 5,500,000 shares of common stock at $5.00 per share, generating gross proceeds of approximately $27.5 million before deductions. Roth Capital Partners served as the joint book-running manager for the offering, which began trading under the ticker symbol 'CV' on July 2, 2025. Additionally, underwriters were granted a 30-day option to purchase up to an additional 825,000 shares at the IPO price.
This IPO represents a pivotal moment for CapsoVision, enabling the company to further its mission of revolutionizing gastrointestinal diagnostics through innovative, AI-driven capsule endoscopy technologies. The successful capital raise underscores investor confidence in CapsoVision's potential to impact the medical technology sector significantly. For more details on the offering, visit https://ibn.fm/D3xFn.
The involvement of Roth Capital Partners, a renowned investment bank focused on growth companies, highlights the strategic importance of this IPO. Roth's expertise in capital raising and equity research has been instrumental in navigating CapsoVision through the public offering process, setting a solid foundation for the company's future growth and innovation in the medical technology industry.
